N 2 8 2009	Ц	PTO/SB/21 (12-08) Approved for use through 01/31/2009. OMB 0651-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995.	no persons are required to respond to a co	ellection of information unless it displays a valid OMB control number.
C and the control of	Application Number	10/565,657
TRANSMITTAL	Filing Date	Oct. 5, 2006 (371(c) Date)
FORM	First Named Inventor	Neel Kumar ANAND
FORW	Art Unit	1625
	Examiner Name	1023
(to be used for all correspondence after initial fi		Zinna Northington DAVIS
Total Number of Pages in This Submission	57 Attorney Docket Number	EX04-017C-US
5101001050		
ENCLOSURES (Check all that apply)		
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		Address Other Enclosure(s) (please Identify below): 1) Second Preliminary Amendment (56 pages). 2) Return Receipt Postcard.
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name		
Exelixis, Inc.	- A- D =	
Signature Minu N. Nice		
Printed name Janice V. Rice		
Date January 28, 2009		Reg. No. 50,606
CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:		
Signature Runa Q. Auntington		
Typed or printed name Laura A. Huntington Date January 28, 2009		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 56

Attorney Docket No.: EX04-017C-US

USSN: 10/565,657



PATENT

Express Mail Tracking Number: EV 938 354 435 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First named Inventor: Anand, Neel Kumar Application No.: 10/565,657

371(c) Date: October 5, 2006 **Group Art Unit:** 1625

Confirmation No.: 6136 **Examiner:** Davis, Zinna Northington

Title: Anaplastic Lymphoma Kinase Modulators and Methods of Use

SECOND PRELIMINARY AMENDMENT

Commissioner for Patents Post Office Box 1450 Washington, D.C. 22313-1450

Dear Sir:

Please enter the following amendments to the Specification, cancel Claims 1-30, and add new Claims 31-58. No new matter is added and support for the changes can be found throughout the Specification.

Amendments to the Specification begin on page 2 of this correspondence.

Cancellation of claims and addition of new claims are given in the listing of Claims which begins on page 9 of this correspondence.

Remarks begin on page 56.